Trial Profile
A Phase I, Multicenter, Open-label Dose Finding Study of NJH395, Administered Intravenously in Patients With Non-breast HER2+ Advanced Malignancies
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 15 Dec 2021
Price :
$35
*
At a glance
- Drugs NJH-395 (Primary)
- Indications Solid tumours
- Focus Adverse reactions; First in man
- Sponsors Novartis Pharmaceuticals
- 11 Nov 2020 Status changed from active, no longer recruiting to completed.
- 21 Sep 2020 Planned primary completion date changed from 31 Aug 2020 to 21 Oct 2020.
- 26 Aug 2020 Planned End Date changed from 6 Aug 2020 to 22 Oct 2020.